Form 4: United Therapeutics CEO Executes Stock Option Plan

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• The acquired shares were subsequently sold in multiple transactions on May 21, 2026.
• The sales were executed at weighted average prices ranging from $557.85 to $566.42 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales are part of a pre-disclosed, systematic trading plan rather than discretionary selling.

Positives

• The transactions were executed under a pre-planned 10b5-1 program, indicating a systematic approach to liquidity rather than reactive selling.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including direct holdings and various family trusts.

Negatives

• The transaction results in a reduction of the CEO's direct beneficial ownership of common stock.

Risks

• The 10b5-1 plan is scheduled to continue until December 31, 2026, or until 1,734,410 options are exercised, which may lead to ongoing periodic selling pressure.

Future Outlook

The reporting person intends to continue exercising and selling shares under the established 10b5-1 plan until the earlier of December 31, 2026, or the exhaustion of 1,734,410 options.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by high-profile biotech executives are standard practice for wealth diversification and do not typically signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard corporate governance practice among S&P 500 and biotech executives to avoid allegations of insider trading.
• The scale of the sale relative to the CEO's total holdings remains consistent with typical executive diversification strategies.

Related Party Transactions

• The filing discloses holdings held in various family trusts and by the reporting person's spouse.

Stakeholder Impact

• Shareholders should view this as a planned liquidity event for the CEO, which is unlikely to impact long-term operational strategy.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options, Biotech